Advertisement

Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition

Published:March 10, 2021DOI:https://doi.org/10.1016/j.jcyt.2020.11.007

      Abstract

      The International Society for Cell & Gene Therapy mesenchymal stromal cell (MSC) committee has been an interested observer of community interests in all matters related to MSC identity, mechanism of action, potency assessment and etymology, and it has regularly contributed to this conversation through a series of MSC pre-conferences and committee publications dealing with these matters. Arising from these reflections, the authors propose that an overlooked and potentially disruptive perspective is the impact of in vivo persistence on potency that is not predicted by surrogate cellular potency assays performed in vitro and how this translates to in vivo outcomes. Systemic delivery or extravascular implantation at sites removed from the affected organ system seems to be adequate in affecting clinical outcomes in many pre-clinical murine models of acute tissue injury and inflammatory pathology, including the recent European Medicines Agency-approved use of MSCs in Crohn-related fistular disease. The authors further propose that MSC viability and metabolic fitness likely dominate as a potency quality attribute, especially in recipients poised for salutary benefits as defined by emerging predictive biomarkers of response.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Viswanathan S.
        • Shi Y.
        • Galipeau J.
        • Krampera M.
        • Leblanc K.
        • Martin I.
        • et al.
        Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT(R)) Mesenchymal Stromal Cell committee position statement on nomenclature.
        Cytotherapy. 2019; 21: 1019-1024
        • Lazarus H.M.
        • Haynesworth S.E.
        • Gerson S.L.
        • Rosenthal N.S.
        • Caplan A.I.
        Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use.
        Bone Marrow Transplant. 1995; 16: 557-564
        • Panes J.
        • Garcia-Olmo D.
        • Van Assche G.
        • Colombel J.F.
        • Reinisch W.
        • Baumgart D.C.
        • et al.
        Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
        Lancet. 2016; 388: 1281-1290
        • Panes J.
        • Garcia-Olmo D.
        • Van Assche G.
        • Colombel J.F.
        • Reinisch W.
        • Baumgart D.C.
        • et al.
        Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.
        Gastroenterology. 2018; 154: 1334-1342.e4
        • Hoogduijn M.J.
        • Lombardo E.
        Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review.
        Stem Cells Transl Med. 2019; 8: 1126-1134
        • Crane G.M.
        • Jeffery E.
        • Morrison S.J.
        Adult haematopoietic stem cell niches.
        Nat Rev Immunol. 2017; 17: 573-590
        • Farahani R.M.
        • Xaymardan M.
        Platelet-Derived Growth Factor Receptor Alpha as a Marker of Mesenchymal Stem Cells in Development and Stem Cell Biology.
        Stem Cells Int. 2015; 2015362753
        • Mabuchi Y.
        • Matsuzaki Y.
        Prospective isolation of resident adult human mesenchymal stem cell population from multiple organs.
        Int J Hematol. 2016; 103: 138-144
        • Wei Q.
        • Frenette P.S.
        Niches for Hematopoietic Stem Cells and Their Progeny.
        Immunity. 2018; 48: 632-648
        • Kfoury Y.
        • Scadden D.T.
        Mesenchymal cell contributions to the stem cell niche.
        Cell Stem Cell. 2015; 16: 239-253
        • Tikhonova A.N.
        • Dolgalev I.
        • Hu H.
        • Sivaraj K.K.
        • Hoxha E.
        • Cuesta-Dominguez A.
        • et al.
        The bone marrow microenvironment at single-cell resolution.
        Nature. 2019; 569: 222-228
        • Zhou B.O.
        • Yue R.
        • Murphy M.M.
        • Peyer J.G.
        • Morrison S.J.
        Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow.
        Cell Stem Cell. 2014; 15: 154-168
        • Matsuzaki Y.
        • Mabuchi Y.
        • Okano H.
        Leptin receptor makes its mark on MSCs.
        Cell Stem Cell. 2014; 15: 112-114
        • Id Boufker H.
        • Lagneaux L.
        • Najar M.
        • Piccart M.
        • Ghanem G.
        • Body J.J.
        • et al.
        The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
        BMC Cancer. 2010; 10: 298
        • Ghazanfari R.
        • Li H.
        • Zacharaki D.
        • Lim H.C.
        • Scheding S.
        Human Non-Hematopoietic CD271pos/CD140alow/neg Bone Marrow Stroma Cells Fulfill Stringent Stem Cell Criteria in Serial Transplantations.
        Stem Cells Dev. 2016; 25: 1652-1658
        • Lo Furno D.
        • Mannino G.
        • Cardile V.
        • Parenti R.
        • Giuffrida R.
        Potential Therapeutic Applications of Adipose-Derived Mesenchymal Stem Cells.
        Stem Cells Dev. 2016; 25: 1615-1628
        • Dominici M.
        • Le Blanc K.
        • Mueller I.
        • Slaper-Cortenbach I.
        • Marini F.
        • Krause D.
        • et al.
        Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
        Cytotherapy. 2006; 8: 315-317
        • Phinney D.G.
        • Galipeau J.
        • Gene T.
        • Msc Committee Of The International Society Of, C. &
        Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers.
        Cytotherapy. 2019; 21: 782-792
        • Menard C.
        • Dulong J.
        • Roulois D.
        • Hebraud B.
        • Verdiere L.
        • Pangault C.
        • et al.
        Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells.
        Stem Cells. 2020; 38: 146-159
        • Ho Y.T.
        • Shimbo T.
        • Wijaya E.
        • Ouchi Y.
        • Takaki E.
        • Yamamoto R.
        • et al.
        Chromatin accessibility identifies diversity in mesenchymal stem cells from different tissue origins.
        Sci Rep. 2018; 8: 17765
        • Cho K.A.
        • Park M.
        • Kim Y.H.
        • Woo S.Y.
        • Ryu K.H.
        RNA sequencing reveals a transcriptomic portrait of human mesenchymal stem cells from bone marrow, adipose tissue, and palatine tonsils.
        Sci Rep. 2017; 7: 17114
        • Farahani R.M.
        • Xaymardan M.
        Platelet-Derived Growth Factor Receptor Alpha as a Marker of Mesenchymal Stem Cells in Development and Stem Cell Biology.
        Stem Cells Int. 2015; 2015362753
        • Bara J.J.
        • Richards R.G.
        • Alini M.
        • Stoddart M.J.
        Concise review: bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic.
        Stem Cells. 2014; 32: 1713-1723
        • Shi Y.
        • Wang Y.
        • Li Q.
        • Liu K.
        • Hou J.
        • Shao C.
        • et al.
        Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases.
        Nat Rev Nephrol. 2018; 14: 493-507
        • Selich A.
        • Daudert J.
        • Hass R.
        • Philipp F.
        • von Kaisenberg C.
        • Paul G.
        • et al.
        Massive Clonal Selection and Transiently Contributing Clones During Expansion of Mesenchymal Stem Cell Cultures Revealed by Lentiviral RGB-Barcode Technology.
        Stem Cells Transl Med. 2016; 5: 591-601
        • Phinney D.G.
        Functional heterogeneity of mesenchymal stem cells: implications for cell therapy.
        J Cell Biochem. 2012; 113: 2806-2812
        • Boregowda S.V.
        • Krishnappa V.
        • Haga C.L.
        • Ortiz L.A.
        • Phinney D.G.
        A Clinical Indications Prediction Scale Based on TWIST1 for Human Mesenchymal Stem Cells.
        EBioMedicine. 2016; 4: 62-73
        • Galipeau J.
        • Sensebe L.
        Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.
        Cell Stem Cell. 2018; 22: 824-833
        • Shi C.
        • Jia T.
        • Mendez-Ferrer S.
        • Hohl T.M.
        • Serbina N.V.
        • Lipuma L.
        • et al.
        Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands.
        Immunity. 2011; 34: 590-601
        • Rafei M.
        • Hsieh J.
        • Fortier S.
        • Li M.
        • Yuan S.
        • Birman E.
        • et al.
        Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction.
        Blood. 2008; 112: 4991-4998
        • Takeda K.
        • Webb T.L.
        • Ning F.
        • Shiraishi Y.
        • Regan D.P.
        • Chow L.
        • et al.
        Mesenchymal Stem Cells Recruit CCR2+ Monocytes To Suppress Allergic Airway Inflammation.
        J Immunol. 2018; 200: 1261-1269
        • Lee H.K.
        • Kim H.S.
        • Kim J.S.
        • Kim Y.G.
        • Park K.H.
        • Lee J.H.
        • et al.
        CCL2 deficient mesenchymal stem cells fail to establish long-lasting contact with T cells and no longer ameliorate lupus symptoms.
        Sci Rep. 2017; 7: 41258
        • Giri J.
        • Das R.
        • Nylen E.
        • Chinnadurai R.
        • Galipeau J.
        CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury.
        Cell Rep. 2020; 30: 1923-1934.e4
        • Chan J.K.
        • Roth J.
        • Oppenheim J.J.
        • Tracey K.J.
        • Vogl T.
        • Feldmann M.
        • et al.
        Alarmins: awaiting a clinical response.
        J Clin Invest. 2012; 122: 2711-2719
        • Lee G.
        • Espirito Santo A.I.
        • Zwingenberger S.
        • Cai L.
        • Vogl T.
        • Feldmann M.
        • et al.
        Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert.
        Proc Natl Acad Sci U S A. 2018; 115: E4463-E4472
        • Beegle J.
        • Lakatos K.
        • Kalomoiris S.
        • Stewart H.
        • Isseroff R.R.
        • Nolta J.A.
        • et al.
        Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo.
        Stem Cells. 2015; 33: 1818-1828
        • Yin J.Q.
        • Zhu J.
        • Ankrum J.A.
        Manufacturing of primed mesenchymal stromal cells for therapy.
        Nat Biomed Eng. 2019; 3: 90-104
        • Chinnadurai R.
        • Rajan D.
        • Qayed M.
        • Arafat D.
        • Garcia M.
        • Liu Y.
        • et al.
        Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach.
        Cell Rep. 2018; 22: 2504-2517
        • Pittenger M.F.
        • Discher D.E.
        • Peault B.M.
        • Phinney D.G.
        • Hare J.M.
        • Caplan A.I.
        Mesenchymal stem cell perspective: cell biology to clinical progress.
        NPJ Regen Med. 2019; 4: 22
        • Carvalho A.E.S.
        • Sousa M.R.R.
        • Alencar-Silva T.
        • Carvalho J.L.
        • Saldanha-Araujo F
        Mesenchymal stem cells immunomodulation: the road to IFN-gamma licensing and the path ahead.
        Cytokine Growth Factor Rev. 2019; 47: 32-42
        • Gnani D.
        • Crippa S.
        • Della Volpe L.
        • Rossella V.
        • Conti A.
        • Lettera E.
        • et al.
        An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program.
        Aging Cell. 2019; 18: e12933
        • Spees J.L.
        • Lee R.H.
        • Gregory C.A.
        Mechanisms of mesenchymal stem/stromal cell function.
        Stem Cell Res Ther. 2016; 7: 125
        • Phinney D.G.
        • Pittenger M.F.
        Concise Review: MSC-Derived Exosomes for Cell-Free Therapy.
        Stem Cells. 2017; 35: 851-858
        • Elahi F.M.
        • Farwell D.G.
        • Nolta J.A.
        • Anderson J.D.
        Preclinical translation of exosomes derived from mesenchymal stem/stromal cells.
        Stem Cells. 2020; 38: 15-21
        • Dal Collo G.
        • Adamo A.
        • Gatti A.
        • Tamellini E.
        • Bazzoni R.
        • Takam Kamga P.
        • et al.
        Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease.
        Stem Cells. 2020; 38: 698-711
        • Mendt M.
        • Rezvani K.
        • Shpall E.
        Mesenchymal stem cell-derived exosomes for clinical use.
        Bone Marrow Transplant. 2019; 54: 789-792
        • Tieu A.
        • Slobodian M.
        • Fergusson D.A.
        • Montroy J.
        • Burger D.
        • Stewart D.J.
        • et al.
        Methods and efficacy of extracellular vesicles derived from mesenchymal stromal cells in animal models of disease: a preclinical systematic review protocol.
        Syst Rev. 2019; 8: 322
        • Luk F.
        • de Witte S.F.
        • Korevaar S.S.
        • Roemeling-van Rhijn M.
        • Franquesa M.
        • Strini T.
        • et al.
        Inactivated Mesenchymal Stem Cells Maintain Immunomodulatory Capacity.
        Stem Cells Dev. 2016; 25: 1342-1354
        • Lee O.J.
        • Luk F.
        • Korevaar S.S.
        • Koch T.G.
        • Baan C.C.
        • Merino A.
        • et al.
        The Importance of Dosing, Timing, and (in)Activation of Adipose Tissue-Derived Mesenchymal Stromal Cells on Their Immunomodulatory Effects.
        Stem Cells Dev. 2020; 29: 38-48
        • de Witte S.F.H.
        • Luk F.
        • Sierra Parraga J.M.
        • Gargesha M.
        • Merino A.
        • Korevaar S.S.
        Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells.
        Stem Cells. 2018; 36: 602-615
        • Oja S.
        • Kaartinen T.
        • Ahti M.
        • Korhonen M.
        • Laitinen A.
        • Nystedt J.
        The Utilization of Freezing Steps in Mesenchymal Stromal Cell (MSC) Manufacturing: Potential Impact on Quality and Cell Functionality Attributes.
        Front Immunol. 2019; 10: 1627
        • Weiss D.J.
        • English K.
        • Krasnodembskaya A.
        • Isaza-Correa J.M.
        • Hawthorne I.J.
        • Mahon B.P.
        The Necrobiology of Mesenchymal Stromal Cells Affects Therapeutic Efficacy.
        Front Immunol. 2019; 10: 1228
        • Galleu A.
        • Riffo-Vasquez Y.
        • Trento C.
        • Lomas C.
        • Dolcetti L.
        • Cheung T.S.
        • et al.
        Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.
        Sci Transl Med. 2017; : eaam7828
        • Matthay M.A.
        • Calfee C.S.
        • Zhuo H.
        • Thompson B.T.
        • Wilson J.G.
        • Levitt J.E.
        • et al.
        Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
        Lancet Respir Med. 2019; 7: 154-162
        • Moll G.
        • Geissler S.
        • Catar R.
        • Ignatowicz L.
        • Hoogduijn M.J.
        • Strunk D.
        • et al.
        Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?.
        Adv Exp Med Biol. 2016; 951: 77-98
        • Chinnadurai R.
        • Copland I.B.
        • Garcia M.A.
        • Petersen C.T.
        • Lewis C.N.
        • Waller E.K.
        • et al.
        Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNgamma Licensing.
        Stem Cells. 2016; 34: 2429-2442
        • Braid L.R.
        • Wood C.A.
        • Wiese D.M.
        • Ford B.N.
        Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes.
        Cytotherapy. 2018; 20: 232-244
        • Giri J.
        • Galipeau J.
        Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match.
        Blood Adv. 2020; 4: 1987-1997
        • Allen A.
        • Vaninov N.
        • Li M.
        • Nguyen S.
        • Igo P.
        • Tilles A.W.
        • et al.
        Mesenchymal Stromal Cell Bioreactor for Ex Vivo Reprogramming of Human Immune Cells.
        Sci Rep. 2020; 10: 10142
        • Kabat M.
        • Bobkov I.
        • Kumar S.
        • Grumet M.
        Trends in mesenchymal stem cell clinical trials 2004-2018: is efficacy optimal in a narrow dose range?.
        Stem Cells Transl Med. 2020; 9: 17-27
        • Meyerrose T.
        • Olson S.
        • Pontow S.
        • Kalomoiris S.
        • Jung Y.
        • Annett G.
        • et al.
        Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.
        Adv Drug Deliv Rev. 2010; 62: 1167-1174
        • Mao A.S.
        • Ozkale B.
        • Shah N.J.
        • Vining K.H.
        • Descombes T.
        • Zhang L.
        • et al.
        Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation.
        Proc Natl Acad Sci U S A. 2019; 116: 15392-15397
        • Daga A.
        • Muraglia A.
        • Quarto R.
        • Cancedda R.
        • Corte G.
        Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice.
        Gene Ther. 2002; 9: 915-921
        • Bartunek J.
        • Davison B.
        • Sherman W.
        • Povsic T.
        • Henry T.D.
        • Gersh B.
        • et al.
        Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design.
        Eur J Heart Fail. 2016; 18: 160-168
        • Teerlink J.R.
        • Metra M.
        • Filippatos G.S.
        • Davison B.A.
        • Bartunek J.
        • Terzic A.
        • et al.
        Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.
        Eur J Heart Fail. 2017; 19: 1520-1529
        • Bartolucci J.
        • Verdugo F.J.
        • Gonzalez P.L.
        • Larrea R.E.
        • Abarzua E.
        • Goset C.
        • et al.
        Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
        Circ Res. 2017; 121: 1192-1204
        • Lankford K.L.
        • Arroyo E.J.
        • Nazimek K.
        • Bryniarski K.
        • Askenase P.W.
        • Kocsis J.D.
        Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord.
        PLoS One. 2018; 13e0190358
        • Sensebe L.
        • Fleury-Cappellesso S.
        Biodistribution of mesenchymal stem/stromal cells in a preclinical setting.
        Stem Cells Int. 2013; 2013678063
        • von Bahr L.
        • Batsis I.
        • Moll G.
        • Hagg M.
        • Szakos A.
        • Sundberg B.
        • et al.
        Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation.
        Stem Cells. 2012; 30: 1575-1578
        • Caplan H.
        • Olson S.D.
        • Kumar A.
        • George M.
        • Prabhakara K.S.
        • Wenzel P.
        • et al.
        Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application.
        Front Immunol. 2019; 10: 1645
        • Moll G.
        • Ankrum J.A.
        • Kamhieh-Milz J.
        • Bieback K.
        • Ringden O.
        • Volk H.D.
        • et al.
        Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines.
        Trends Mol Med. 2019; 25: 149-163
        • Guess A.J.
        • Daneault B.
        • Wang R.
        • Bradbury H.
        • La Perle K.M.D.
        • Fitch J.
        • et al.
        Safety Profile of Good Manufacturing Practice Manufactured Interferon Gamma-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials.
        Stem Cells Transl Med. 2017; 6: 1868-1879
        • Kimbrel E.A.
        • Lanza R.
        Next-generation stem cells—ushering in a new era of cell-based therapies.
        Nat Rev Drug Discov. 2020; 19: 463-479
        • Nolta J.A.
        • Galipeau J.
        • Phinney D.G.
        Improving mesenchymal stem/stromal cell potency and survival: proceedings from the International Society of Cell Therapy (ISCT) MSC preconference held in May 2018, Palais des Congres de Montreal, Organized by the ISCT MSC Scientific Committee.
        Cytotherapy. 2020; 22: 123-126
        • Martin I.
        • Galipeau J.
        • Kessler C.
        • Le Blanc K.
        • Dazzi F.
        Challenges for mesenchymal stromal cell therapies.
        Sci Transl Med. 2019; 11: eaat2189
        • Kurtzberg J.
        • Prasad V.
        • Grimley M.
        • Horn B.
        • Carpenter P.
        • Jacobsohn D.
        • et al.
        Allogeneic human mesenchymal stem cell therapy (Prochymal®) as a rescue agent for severe treatment resistant GVHD in pediatric patients.
        Biology of Blood and Marrow Transplantation. 2010; 16: S169
        • Cheung T.S.
        • Bertolino G.M.
        • Giacomini C.
        • Bornhauser M.
        • Dazzi F.
        • Galleu A.
        Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers.
        Front Immunol. 2020; 11: 1338